| LDR | | 05608cam a2200817 i 4500 |
| 001 | | 000000410558 |
| 005 | | 20190131141227 |
| 006 | | m d |
| 007 | | cr bn||||||||| |
| 008 | | 160702s2016 dcu obt 100 0 eng |
| 016 | 7 |
▼a 101686988
▼2 DNLM |
| 020 | |
▼a 9780309380997 |
| 020 | |
▼a 0309380995 |
| 020 | |
▼a 9780309381000 |
| 020 | |
▼a 0309381002 |
| 035 | |
▼a 1159281
▼b (N$T) |
| 035 | |
▼a (OCoLC)949829885 |
| 040 | |
▼a NLM
▼b eng
▼e rda
▼e pn
▼c NLM
▼d CUS
▼d N$T
▼d OCLCF
▼d DOS
▼d OCLCO
▼d OCLCA
▼d YDX
▼d SNK
▼d DKU
▼d INTCL
▼d IGB
▼d D6H
▼d VTS
▼d EZ9
▼d AGLDB
▼d OCLCQ
▼d 247004 |
| 042 | |
▼a pcc |
| 050 | 4 |
▼a RA651
▼b .W594 2016eb |
| 060 | 00 |
▼a 2016 F-679 |
| 060 | 10 |
▼a WA 110 |
| 072 | 7 |
▼a MED
▼x 030000
▼2 bisacsh |
| 072 | 7 |
▼a MED
▼x 076000
▼2 bisacsh |
| 072 | 7 |
▼a MED
▼x 078000
▼2 bisacsh |
| 082 | 04 |
▼a 614.4
▼2 23 |
| 100 | 1 |
▼a Wizemann, Theresa M.,
▼e rapporteur. |
| 245 | 10 |
▼a Global health risk framework :
▼b research and development of medical products : workshop summary/
▼c Theresa Wizemann, Michelle A. Mancher, and Anne B. Claiborne, rapporteurs ; Board of Health Sciences Policy, Institute of Medicine, the National Academies of Sciences, Engineering, Medicine. |
| 260 | |
▼a Washington, DC:
▼b National Academies Press,
▼c [2016]. |
| 300 | |
▼a 1 online resource (1 PDF file (xvi, 123 pages)). |
| 336 | |
▼a text
▼b txt
▼2 rdacontent |
| 337 | |
▼a computer
▼b c
▼2 rdamedia |
| 338 | |
▼a online resource
▼b cr
▼2 rdacarrier |
| 500 | |
▼a Workshop agenda, August 19-21, 2015, Cheung Kung Hai Conference Centre, Hong Kong. |
| 504 | |
▼a Includes bibliographical references. |
| 505 | 0 |
▼a Introduction -- Models and incentives for engagement -- Discovery research -- Development -- Convergence of regulatory expections, review, and approval -- Manufacturing, stockpiling, and distribution -- Critical considerations for facilitating medical product research and development -- Crosscutting themes and closing remarks -- Appendix A: References -- Appendix B: Workshop statement of task -- Appendix C: Workshop agenda -- Appendix D: Workshop speaker biographies. |
| 520 | 3 |
▼a Since the 2014 Ebola outbreak many public- and private-sector leaders have seen a need for improved management of global public health emergencies. The effects of the Ebola epidemic go well beyond the three hardest-hit countries and beyond the health sector. Education, child protection, commerce, transportation, and human rights have all suffered. The consequences and lethality of Ebola have increased interest in coordinated global response to infectious threats, many of which could disrupt global health and commerce far more than the recent outbreak. In order to explore the potential for improving international management and response to outbreaks the National Academy of Medicine agreed to manage an international, independent, evidence-based, authoritative, multistakeholder expert commission. As part of this effort, the Institute of Medicine convened four workshops in summer of 2015 to inform the commission report. The presentations and discussions from the Workshop on Research and Development of Medical Products are summarized in this report. |
| 536 | |
▼a This activity was supported by Sponsor Award No. 11849 from the Paul G. Allen Family Foundation, Grant No. 0150-0653 from the Ford Foundation, Investment ID OPP1130763 from The Bill & Melinda Gates Foundation, Dr. Ming Wai Lau, Grant No. 4829 from the Gordon and Betty Moore Foundation, Grant No. 2015 EBO 308 from The Rockefeller Foundation, Award No. GHN-G-00-07-00001-00 from the U.S. Agency for International Development, and the Wellcome Trust. Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project. |
| 588 | 0 |
▼a Online resource; title from PDF title page (viewed July 29, 2016). |
| 590 | |
▼a Master record variable field(s) change: 050 |
| 650 | 0 |
▼a Diseases
▼x Risk factors. |
| 650 | 0 |
▼a World health. |
| 650 | 0 |
▼a Epidemiology. |
| 650 | 0 |
▼a Mortality. |
| 650 | 12 |
▼a Communicable Disease Control. |
| 650 | 22 |
▼a Vaccines. |
| 650 | 22 |
▼a Pandemics
▼x prevention & control. |
| 650 | 22 |
▼a Drug Discovery. |
| 650 | 22 |
▼a International Cooperation. |
| 650 | 22 |
▼a Global Health. |
| 650 | 7 |
▼a MEDICAL
▼x Forensic Medicine.
▼2 bisacsh |
| 650 | 7 |
▼a MEDICAL
▼x Preventive Medicine.
▼2 bisacsh |
| 650 | 7 |
▼a MEDICAL
▼x Public Health.
▼2 bisacsh |
| 650 | 7 |
▼a Diseases
▼x Risk factors.
▼2 fast
▼0 (OCoLC)fst00895194 |
| 650 | 7 |
▼a Epidemiology.
▼2 fast
▼0 (OCoLC)fst00914091 |
| 650 | 7 |
▼a Mortality.
▼2 fast
▼0 (OCoLC)fst01026502 |
| 650 | 7 |
▼a World health.
▼2 fast
▼0 (OCoLC)fst01181338 |
| 655 | 2 |
▼a Congresses. |
| 655 | 4 |
▼a Electronic books. |
| 700 | 1 |
▼a Mancher, Michelle,
▼e rapporteur, |
| 700 | 1 |
▼a Claiborne, Anne B.,
▼e rapporteur, |
| 710 | 2 |
▼a Institute of Medicine (U.S.).
▼b Board on Health Sciences Policy,
▼e issuing body. |
| 710 | 2 |
▼a National Academies of Sciences, Engineering, and Medicine (U.S.),
▼e issuing body. |
| 711 | 2 |
▼a Global Health Risk Framework: Research and Development of Medical Products (Workshop)
▼d (2015 :
▼c Hong Kong, China),
▼j author. |
| 776 | 08 |
▼i Print version:
▼a Wizemann, Theresa.
▼t Global health risk framework.
▼d [S.l.] : National Academies Press, 2016
▼z 0309380995
▼w (OCoLC)936083366 |
| 856 | 40 |
▼3 EBSCOhost
▼u http://libproxy.dhu.ac.kr/_Lib_Proxy_Url/http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=1159281 |
| 938 | |
▼a EBSCOhost
▼b EBSC
▼n 1159281 |
| 938 | |
▼a YBP Library Services
▼b YANK
▼n 12995916 |
| 990 | |
▼a ***1012033 |
| 994 | |
▼a 92
▼b N$T |